Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity
Shin Foong Ngiow, Sasikanth Manne, Yinghui Huang, et al.
Cell (2024) Vol. 187, Iss. 16, pp. 4336-4354.e19
Closed Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity
Lawrence P. Andrews, Samuel C. Butler, Jian Cui, et al.
Cell (2024) Vol. 187, Iss. 16, pp. 4355-4372.e22
Closed Access | Times Cited: 59
Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity
Anthony R. Cillo, Carly Cardello, Feng Shan, et al.
Cell (2024) Vol. 187, Iss. 16, pp. 4373-4388.e15
Closed Access | Times Cited: 42
Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies
Nicolas Roussot, Courèche Kaderbhaï, François Ghiringhelli
Cancers (2025) Vol. 17, Iss. 5, pp. 906-906
Open Access | Times Cited: 1
Continuous expression of TOX safeguards exhausted CD8 T cell epigenetic fate
Yinghui Huang, Shin Foong Ngiow, Amy E. Baxter, et al.
Science Immunology (2025) Vol. 10, Iss. 105
Closed Access | Times Cited: 1
Comprehensive review of non-invasive treatment related cardiovascular toxicity in breast cancer
C Li, Huijuan Dai, Xinning Guo, et al.
iScience (2025) Vol. 28, Iss. 4, pp. 111759-111759
Closed Access
LAG3+ CD8+ T cell Subset Boosts Bispecific Antibody Armed Activated T Cell Cytotoxicity Directed at Hormone Receptor+ Breast Cancers
Robert Barnes, Archana Thakur, Suna Önengüt-Gümüşcü, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
LAG Time in the Era of Immunotherapy—New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene‐3
Vincent C. Luca
Immunological Reviews (2025) Vol. 330, Iss. 1
Closed Access
Humanizing a CD28 signaling domain affects CD8 activation, exhaustion and stem-like precursors
Alexander Brady, Shankar Revu, Dongwen Wu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs
Yong Jiang, Anran Dai, Yuwei Huang, et al.
Cell (2025)
Open Access
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Stephen L. Wang, Timothy A. Chan
Cancer Cell (2025)
Closed Access
The response to anti–PD-1 and anti–LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming
Annah S. Rolig, Xiyu Peng, Elizabeth R. Sturgill, et al.
Science Translational Medicine (2025) Vol. 17, Iss. 793
Closed Access
LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy
Camil Ciprian Mireștean, Roxana Irina Iancu, Dragoș Petru Teodor Iancu
Current Oncology (2025) Vol. 32, Iss. 4, pp. 230-230
Open Access
Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation
Jing-Lu Yu, Xiaoni Kong, Yu Feng
Cancer Drug Resistance (2025)
Open Access
Resistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils
Xiaocheng Wang, Maosheng Cheng, Shuang Chen, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Elevated KIF2C Expression Drives Osteosarcoma Progression by Modulating the Wnt/β‐Catenin Signaling Pathway and Contributing to an Immunosuppressive Tumor Microenvironment
Yayun Liu, Wu Sun, Lin Liu, et al.
Cancer Medicine (2025) Vol. 14, Iss. 9
Open Access
CD8+ T-cell exhaustion: Impediment to triple-negative breast cancer (TNBC) immunotherapy
Dandan Feng, Dongqing Pu, Juan Ren, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189193-189193
Closed Access | Times Cited: 3
PD-1 and LAG-3: synergistic fostering of T cell exhaustion
Maike Hofmann, Robert Thimme, Wolfgang W. Schamel
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 3
Anti-LAG-3 boosts CD8 T cell effector function
Courtney T.S. Kureshi, Michael Dougan, Stephanie K. Dougan
Cell (2024) Vol. 187, Iss. 16, pp. 4144-4146
Closed Access | Times Cited: 2
Siglec‐G Suppresses CD8+ T Cells Responses through Metabolic Rewiring and Can be Targeted to Enhance Tumor Immunotherapy
Shenhui Yin, Chunzhen Li, Xin Shen, et al.
Advanced Science (2024) Vol. 11, Iss. 45
Open Access | Times Cited: 2
Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials
Rende Mu, Hayam Hamdy, Abdo Meyiah, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Advances in LAG3 cancer immunotherapeutics
Kieran Adam, Samuel C. Butler, Creg J. Workman, et al.
Trends in cancer (2024)
Closed Access | Times Cited: 2
Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer
Caroline Taylor, Kamai M. Patterson, Devira Friedman, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 3071-3071
Open Access | Times Cited: 1
Functional subsets of tumor-specific CD8+ T cells in draining lymph nodes and tumor microenvironment
Qizhao Huang, Lifan Xu, Lilin Ye
Current Opinion in Immunology (2024) Vol. 92, pp. 102506-102506
Closed Access | Times Cited: 1
LAGging behind no more: PD-1 has a new immunotherapy partner
Andrew J. Gunderson
Immunity (2024) Vol. 57, Iss. 10, pp. 2266-2268
Closed Access
No more LAGging behind PD-1: uncovering the unique role of LAG-3 in T-cell exhaustion
Yunju Jo, Hyung‐seung Jin, Yoon Park
Cellular and Molecular Immunology (2024)
Closed Access
Page 1 - Next Page

Scroll to top